{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T09:44:04Z","timestamp":1782899044026,"version":"3.54.5"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,6,26]],"date-time":"2011-06-26T00:00:00Z","timestamp":1309046400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1007\/s11060-011-0642-1","type":"journal-article","created":{"date-parts":[[2011,6,25]],"date-time":"2011-06-25T23:36:48Z","timestamp":1309045008000},"page":"121-125","source":"Crossref","is-referenced-by-count":80,"title":["Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients"],"prefix":"10.1007","volume":"106","author":[{"given":"Andrew D.","family":"Norden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Bartolomeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shota","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Drappatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail S.","family":"Ciampa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"Doherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra C.","family":"LaFrankie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Ruland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eudocia C.","family":"Quant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rameen","family":"Beroukhim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick Y.","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,6,26]]},"reference":[{"key":"642_CR1","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/1097-0142(20000801)89:3<640::AID-CNCR20>3.0.CO;2-E","volume":"89","author":"LC Marras","year":"2000","unstructured":"Marras LC, Geerts WH, Perry JR (2000) The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review. Cancer 89:640\u2013646","journal-title":"Cancer"},{"key":"642_CR2","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1538-7836.2009.03690.x","volume":"8","author":"EO Jenkins","year":"2010","unstructured":"Jenkins EO, Schiff D, Mackman N, Key NS (2010) Venous thromboembolism in malignant gliomas. J Thromb Haemost 8:221\u2013227","journal-title":"J Thromb Haemost"},{"key":"642_CR3","doi-asserted-by":"crossref","first-page":"601","DOI":"10.3171\/jns.2007.106.4.601","volume":"106","author":"TJ Semrad","year":"2007","unstructured":"Semrad TJ, O\u2019Donnell R, Wun T, Chew H, Harvey D, Zhou H, White RH (2007) Epidemiology of venous thromboembolism in 9,489 patients with malignant glioma. J Neurosurg 106:601\u2013608","journal-title":"J Neurosurg"},{"key":"642_CR4","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1016\/S0959-8049(97)00167-6","volume":"33","author":"AA Brandes","year":"1997","unstructured":"Brandes AA, Scelzi E, Salmistraro G, Ermani M, Carollo C, Berti F, Zampieri P, Baiocchi C, Fiorentino MV (1997) Incidence of risk of thromboembolism during treatment high-grade gliomas: a prospective study. Eur J Cancer 33:1592\u20131596","journal-title":"Eur J Cancer"},{"key":"642_CR5","doi-asserted-by":"crossref","unstructured":"Drappatz J, Schiff D, Kesari S, Norden AD, Wen PY (2007) Medical management of brain tumor patients. Neurol Clin 25(4):1035\u20131071, ix","DOI":"10.1016\/j.ncl.2007.07.015"},{"key":"642_CR6","doi-asserted-by":"crossref","first-page":"4865","DOI":"10.1200\/JCO.2009.22.3875","volume":"27","author":"M Zangari","year":"2009","unstructured":"Zangari M, Fink LM, Elice F, Zhan F, Adcock DM, Tricot GJ (2009) Thrombotic events in patients with cancer receiving antiangiogenesis agents. J Clin Oncol 27:4865\u20134873","journal-title":"J Clin Oncol"},{"key":"642_CR7","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1001\/jama.2008.656","volume":"300","author":"SR Nalluri","year":"2008","unstructured":"Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S (2008) Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 300:2277\u20132285","journal-title":"JAMA"},{"key":"642_CR8","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","volume":"27","author":"HS Friedman","year":"2009","unstructured":"Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733\u20134740","journal-title":"J Clin Oncol"},{"key":"642_CR9","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1200\/JCO.2010.30.2729","volume":"29","author":"A Lai","year":"2011","unstructured":"Lai A, Tran A, Nghiemphu PL, Pope WB, Solis OE, Selch M, Filka E, Yong WH, Mischel PS, Liau LM, Phuphanich S, Black K, Peak S, Green RM, Spier CE, Kolevska T, Polikoff J, Fehrenbacher L, Elashoff R, Cloughesy T (2011) Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 29:142\u2013148","journal-title":"J Clin Oncol"},{"key":"642_CR10","doi-asserted-by":"crossref","first-page":"5297","DOI":"10.1002\/cncr.25462","volume":"116","author":"JJ Raizer","year":"2010","unstructured":"Raizer JJ, Grimm S, Chamberlain MC, Nicholas MK, Chandler JP, Muro K, Dubner S, Rademaker AW, Renfrow J, Bredel M (2010) A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas. Cancer 116:5297\u20135305","journal-title":"Cancer"},{"key":"642_CR11","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1212\/01.wnl.0000304121.57857.38","volume":"70","author":"AD Norden","year":"2008","unstructured":"Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy B, Drappatz J, Kesari S, Wen PY (2008) Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70:779\u2013787","journal-title":"Neurology"},{"key":"642_CR12","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1215\/15228517-2008-009","volume":"10","author":"PL Nghiemphu","year":"2008","unstructured":"Nghiemphu PL, Green RM, Pope WB, Lai A, Cloughesy TF (2008) Safety of anticoagulation use and bevacizumab in patients with glioma. Neuro Oncol 10:355\u2013360","journal-title":"Neuro Oncol"},{"key":"642_CR13","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/jama.293.6.715","volume":"293","author":"JW Blom","year":"2005","unstructured":"Blom JW, Doggen CJ, Osanto S, Rosendaal FR (2005) Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 293:715\u2013722","journal-title":"JAMA"},{"key":"642_CR14","doi-asserted-by":"crossref","first-page":"58S","DOI":"10.1378\/chest.124.3_suppl.58S","volume":"124","author":"FR Rickles","year":"2003","unstructured":"Rickles FR, Patierno S, Fernandez PM (2003) Tissue factor, thrombin, and cancer. Chest 124:58S\u201368S","journal-title":"Chest"},{"key":"642_CR15","first-page":"31","volume":"30","author":"PM Fernandez","year":"2004","unstructured":"Fernandez PM, Patierno SR, Rickles FR (2004) Tissue factor and fibrin in tumor angiogenesis. Semin Thromb Hemost 30:31\u201344","journal-title":"Semin Thromb Hemost"},{"key":"642_CR16","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/1097-0142(19920901)70:5<1194::AID-CNCR2820700528>3.0.CO;2-E","volume":"70","author":"NS Callander","year":"1992","unstructured":"Callander NS, Varki N, Rao LV (1992) Immunohistochemical identification of tissue factor in solid tumors. Cancer 70:1194\u20131201","journal-title":"Cancer"},{"key":"642_CR17","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1002\/(SICI)1097-0142(19960501)77:9<1877::AID-CNCR18>3.0.CO;2-X","volume":"77","author":"K Hamada","year":"1996","unstructured":"Hamada K, Kuratsu J, Saitoh Y, Takeshima H, Nishi T, Ushio Y (1996) Expression of tissue factor correlates with grade of malignancy in human glioma. Cancer 77:1877\u20131883","journal-title":"Cancer"},{"key":"642_CR18","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s11060-006-9193-2","volume":"80","author":"PY Wen","year":"2006","unstructured":"Wen PY, Schiff D, Kesari S, Drappatz J, Gigas DC, Doherty L (2006) Medical management of patients with brain tumors. J Neurooncol 80:313\u2013332","journal-title":"J Neurooncol"},{"key":"642_CR19","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1200\/JCO.2005.04.6656","volume":"24","author":"DE Gerber","year":"2006","unstructured":"Gerber DE, Grossman SA, Streiff MB (2006) Management of venous thromboembolism in patients with primary and metastatic brain tumors. J Clin Oncol 24:1310\u20131318","journal-title":"J Clin Oncol"},{"key":"642_CR20","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/archinte.162.15.1729","volume":"162","author":"G Meyer","year":"2002","unstructured":"Meyer G, Marjanovic Z, Valcke J, Lorcerie B, Gruel Y, Solal-Celigny P, Le Maignan C, Extra JM, Cottu P, Farge D (2002) Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 162:1729\u20131735","journal-title":"Arch Intern Med"},{"key":"642_CR21","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","volume":"349","author":"AY Lee","year":"2003","unstructured":"Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M (2003) Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349:146\u2013153","journal-title":"N Engl J Med"},{"key":"642_CR22","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1634\/theoncologist.2009-0121","volume":"14","author":"MH Cohen","year":"2009","unstructured":"Cohen MH, Shen YL, Keegan P, Pazdur R (2009) FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist 14:1131\u20131138","journal-title":"Oncologist"},{"key":"642_CR23","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1097\/00005344-199606000-00011","volume":"27","author":"R Yang","year":"1996","unstructured":"Yang R, Thomas GR, Bunting S, Ko A, Ferrara N, Keyt B, Ross J, Jin H (1996) Effects of vascular endothelial growth factor on hemodynamics and cardiac performance. J Cardiovasc Pharmacol 27:838\u2013844","journal-title":"J Cardiovasc Pharmacol"},{"key":"642_CR24","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1200\/JCO.2008.16.3055","volume":"27","author":"TN Kreisl","year":"2009","unstructured":"Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, Park J, Albert PS, Fine HA (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27:740\u2013745","journal-title":"J Clin Oncol"},{"key":"642_CR25","doi-asserted-by":"crossref","unstructured":"Fraum TJ, Kreisl TN, Sul J, Fine HA, Iwamoto FM (2011) Ischemic stroke and intracranial hemorrhage in glioma patients on antiangiogenic therapy. J Neurooncol","DOI":"10.1007\/s11060-011-0579-4"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-011-0642-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11060-011-0642-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-011-0642-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,12]],"date-time":"2019-06-12T10:15:22Z","timestamp":1560334522000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11060-011-0642-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6,26]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["642"],"URL":"https:\/\/doi.org\/10.1007\/s11060-011-0642-1","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6,26]]}}}